Mibavademab

Phase 3Recruiting

0 views this week 0 watching⚡ Active💉Featured in GLP-1 & Metabolic Watch

Interest: 47/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Monogenic Obesity

Conditions

Monogenic Obesity

Trial Timeline

Feb 9, 2026 → Apr 21, 2028

NCT ID

NCT07220772

About Mibavademab

Mibavademab is a phase 3 stage product being developed by Regeneron Pharmaceuticals for Monogenic Obesity. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07220772. Target conditions include Monogenic Obesity.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07235917	Phase 2	Recruiting	Mar 31, 2026	Dec 8, 2027	Functional Hypothalamic Amenorrhea (FHA)
NCT07220772	Phase 3	Recruiting	Feb 9, 2026	Apr 21, 2028	Monogenic Obesity
NCT06548100	Phase 3	Active	Dec 16, 2024	Nov 3, 2026	Generalized Lipodystrophy

Competing Products

1 competing product in Monogenic Obesity

See all competitors

Product	Company	Stage	Hype Score
Semaglutide (administered by PDS290 pen-injector)	Novo Nordisk	Pre-clinical	33